Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

Recruiting now · Not applicable

Conditions studied: Obesity, Body Composition

In brief

The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.

Key facts

Study ID

NCT07226947

Run by

Massachusetts General Hospital

People needed

100

Starts

2025-11-24

Expected to finish

2027-06-01

Last updated by the study team

2025-12-30

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old at time of signing informed consent
• Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment
• a. Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment
• Able to provide informed consent

You may not qualify if…

• Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
• BMI <25 kg/m2 at the time of screening
• Unable to participate in a regular physical exercise program
• Implanted pacemaker
• Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study

Where it is running

• Diabetes Research Center — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.